Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.76 USD | -3.50% | -10.10% | -14.02% |
Financials (USD)
Sales 2024 * | 42.75K | Sales 2025 * | 4.41M | Capitalization | 471M |
---|---|---|---|---|---|
Net income 2024 * | -283M | Net income 2025 * | -305M | EV / Sales 2024 * | 5,174 x |
Net cash position 2024 * | 250M | Net cash position 2025 * | 284M | EV / Sales 2025 * | 42.4 x |
P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-1.66
x | Employees | 233 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.22% |
Latest transcript on Allogene Therapeutics, Inc.
1 day | -3.50% | ||
1 week | -10.10% | ||
1 month | -27.37% | ||
3 months | -44.35% | ||
6 months | +10.40% | ||
Current year | -14.02% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
David Chang
FOU | Founder | 64 | 18-03-31 |
Geoffrey Parker
DFI | Director of Finance/CFO | 59 | 23-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bonderman
BRD | Director/Board Member | 81 | 18-04-30 |
Joshua Kazam
FOU | Founder | 47 | 17-10-31 |
Arie Belldegrun
FOU | Founder | 74 | 17-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.54% | 2 M€ | -25.75% | ||
0.08% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.76 | -3.50% | 1,020,780 |
24-05-09 | 2.86 | +3.62% | 1,140,704 |
24-05-08 | 2.76 | -5.15% | 1,141,019 |
24-05-07 | 2.91 | -3.32% | 866,952 |
24-05-06 | 3.01 | -1.95% | 1,566,317 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.02% | 471M | |
+3.91% | 109B | |
+10.87% | 105B | |
0.00% | 22.25B | |
-13.14% | 22.09B | |
-8.26% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALLO Stock